Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Catumaxomab: clinical development and future directions.

Rolf Linke¹, Anke Klein, Diane Seimetz

¹Fresenius Biotech GmbH, Munich, Germany.

|March 2, 2010

Summary

Catumaxomab is a novel bispecific antibody for treating malignant ascites in cancer patients. This targeted immunotherapy effectively eliminates EpCAM-positive tumor cells within the peritoneal cavity.

Related Concept Videos

Traumatic Brain Injury l: Introduction

Traumatic Brain Injury l: Introduction

DefinitionTraumatic brain injury, or TBI, is a disturbance of normal brain function induced by an external mechanical force, such as a direct blow to the head or a penetrating injury. It can affect both brain structure and function, producing a wide range of clinical outcomes. TBI is a heterogeneous condition, meaning its effects may differ based on the type, location, and severity of the injury.Basis of ClassificationTBI is classified based on severity, injury mechanism, or pathophysiology. In...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Investigating dysfunctional cognition change as a putative mechanism of CBT for youth anxiety, OCD and PTSD: protocol for an individual participant data meta-analysis.

BMJ open·2025

Same author

Efficacy in patients with <i>EGFR</i>-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050.

Future oncology (London, England)·2024

Same author

Web-Based, Human-Guided, or Computer-Guided Transdiagnostic Cognitive Behavioral Therapy in University Students With Anxiety and Depression: Randomized Controlled Trial.

JMIR mental health·2024

Same author

COVID-19 and mental health among at-risk university students: A prospective study into risk and protective factors.

International journal of methods in psychiatric research·2021

Same author

Online computer or therapist-guided cognitive behavioral therapy in university students with anxiety and/or depression: study protocol of a randomised controlled trial.

BMJ open·2021

Same author

The Associations of Common Psychological Problems With Mental Disorders Among College Students.

Frontiers in psychiatry·2021

Area of Science:

Oncology
Immunotherapy
Monoclonal Antibodies

Background:

Malignant ascites is a common complication of epithelial carcinomas.
Current treatments for malignant ascites have limitations.
EpCAM is a tumor-associated antigen expressed on epithelial carcinomas.

Purpose of the Study:

To review the clinical development of catumaxomab.
To highlight catumaxomab as a targeted immunotherapeutic approach for malignant ascites.
To discuss the potential of catumaxomab for treating various epithelial carcinomas.

Main Methods:

Review of clinical trials and scientific literature on catumaxomab.
Analysis of catumaxomab's mechanism of action.
Evaluation of its efficacy and safety in treating malignant ascites.

Main Results:

Catumaxomab is the first antibody approved for malignant ascites treatment.
It demonstrates efficacy in destroying EpCAM-positive tumor cells intraperitoneally.
Potential therapeutic applications for various epithelial carcinomas due to EpCAM expression.

Conclusions:

Catumaxomab represents a significant advancement in targeted immunotherapy for malignant ascites.
Its mechanism of action offers a promising approach for EpCAM-positive epithelial cancers.
Further clinical development may expand its therapeutic utility.

Related Experiment Videos